Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

HIV-1 drug resistant mutations in chronically infected treatment naive individuals in the pre-ARV era in Nigeria.

Odaibo GN, Ola SO, Landerz M, Dietrich U, Olaleye DO.

Afr J Med Med Sci. 2012 Dec;41 Suppl:61-3.

PMID:
23678638
2.

The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco.

Bakhouch K, Oulad-Lahcen A, Bensghir R, Blaghen M, Elfilali KM, Ezzikouri S, Abidi O, Hassar M, Wakrim L.

J Infect Dev Ctries. 2009 Jun 1;3(5):380-91.

3.

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.

Elmi Abar A, Jlizi A, Darar HY, Kacem MA, Slim A.

Diagn Pathol. 2012 Oct 8;7:138. doi: 10.1186/1746-1596-7-138.

4.

HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.

Aulicino PC, Rocco CA, Mecikovsky D, Bologna R, Mangano A, Sen L.

Antivir Ther. 2010;15(4):641-50. doi: 10.3851/IMP1571.

PMID:
20587857
5.
6.

Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study.

Descamps D, Calvez V, Izopet J, Buffet-Janvresse C, Schmuck A, Colson P, Ruffault A, Maillard A, Masquelier B, Cottalorda J, Harzic M, Brun-Vézinet F, Costagliola D; ANRS Antiretroviral Resistance Study Group..

AIDS. 2001 Sep 28;15(14):1777-82.

PMID:
11579238
7.

Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.

Muñoz M, Carmona R, Pérez-Alvarez L, Cilla G, Suarez MD, Delgado E, Contreras G, Corral J, de Goicoetxea MJ, Medrano L, Lezaún MJ, Nájera R; Spanish Group for Antiretroviral Resistance Studies in Basque Country..

J Clin Virol. 2005 Jul;33(3):224-9.

PMID:
15911444
8.

Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M.

Antivir Ther. 2000 Mar;5(1):7-14.

PMID:
10846586
9.
10.

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Coté P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP.

AIDS. 2000 Jan 28;14(2):F17-23.

PMID:
10708278
11.

Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: analysis of primary resistance mutations.

de Medeiros RM, Junqueira DM, Matte MC, Barcellos NT, Chies JA, Matos Almeida SE.

J Med Virol. 2011 Oct;83(10):1682-8. doi: 10.1002/jmv.22188.

PMID:
21837783
12.

[Prevalence of drug resistance mutations among antiretroviral drug-naive HIV-1-infected patients in China].

Si XF, Huang HL, Wei M, Guan Q, Song YH, Ma PF, Quan Y, Xing H, Shao YM.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2004 Dec;18(4):308-11. Chinese.

PMID:
15650776
13.

Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.

Vázquez de Parga E, Rakhmanova A, Pérez-Alvarez L, Vinogradova A, Delgado E, Thomson MM, Casado G, Sierra M, Muñoz M, Carmona R, Vega Y, Contreras G, Medrano L, Osmanov S, Nájera R.

J Med Virol. 2005 Nov;77(3):337-44.

PMID:
16173024
14.

Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.

Puig T, Pérez-Olmeda M, Rubio A, Ruiz L, Briones C, Franco JM, Gómez-Cano M, Stuyver L, Zamora L, Alvarez C, Leal M, Clotet B, Soriano V.

AIDS. 2000 Apr 14;14(6):727-32.

PMID:
10807196
15.

Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1-infected children.

Almeida FJ, Berezin EN, Rodrigues R, Sáfadi MA, Arnoni MV, Oliveira C, Brígido LF.

J Pediatr (Rio J). 2009 Mar-Apr;85(2):104-9. doi: doi:10.2223/JPED.1877. English, Portuguese.

16.

Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme.

Bellocchi MC, Forbici F, Palombi L, Gori C, Coelho E, Svicher V, D'Arrigo R, Emberti-Gialloreti L, Ceffa S, Erba F, Marazzi MC, Silberstein FC, Perno CF.

J Med Virol. 2005 Aug;76(4):452-8.

PMID:
15977236
17.

Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.

Santoro MM, Svicher V, Gori C, Zaccarelli M, Tozzi V, Forbici F, D'Arrigo R, Trotta MP, Bellocchi MC, Visco-Comandini U, Cenci A, Bertoli A, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F.

New Microbiol. 2006 Apr;29(2):89-100.

PMID:
16841549
18.

Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation.

Perno CF, Cozzi-Lepri A, Balotta C, Bertoli A, Violin M, Monno L, Zauli T, Montroni M, Ippolito G, d'Arminio-Monforte A; I.CO.N.A Study Group..

AIDS. 2002 Mar 8;16(4):619-24.

PMID:
11873006
19.

Frequency of protease and reverse transcriptase drug resistance mutations in naïve HIV-infected patients.

Valle-Bahena OM, Ramos-Jiménez J, Ortiz-López R, Revol A, Lugo-Trampe A, Barrera-Saldaña HA, Rojas-Martínez A.

Arch Med Res. 2006 Nov;37(8):1022-7.

PMID:
17045121
20.

[Background study of HIV-1 drug resistant mutations in treatment-naive patients in liaoning province].

Han XX, Zhang M, Dai D, Lu C, Zhang ZN, Liu J, Wang YN, Jiang YJ, Shang H.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2006 Oct;28(5):632-6. Chinese.

Supplemental Content

Support Center